leadf
logo-loader
viewImugene Ltd

Imugene bolsters executive team with appointment of Dr Rita Laeufle as chief medical officer

The company recently entered into an agreement to underwrite outstanding listed options which provides holders with an option to purchase shares in the company at 2.6 cents per share.

Imugene Ltd - Imugene appoints Dr Rita Laeufle as chief medical officer
Imugene is a clinical stage immune-oncology company developing a range of new and novel immunotherapies

Imugene Ltd (ASX:IMU) has bolstered its executive leadership team through the appointment of Dr Rita Laeufle as chief medical officer.

Laeufle will lead the global clinical development, regulatory and medical monitoring activities, replacing Dr Mark Marino who is stepping down from his position.

As a board-certified surgical oncologist, Laeufle has extensive clinical development experience in immune-oncology studies from phase-1 to phase-3 in breast and gastrointestinal cancers.

She brings deep experience to Imugene, having held senior level clinical development, leadership and senior medical positions at top tier pharmaceuticals companies including Hoffman-La Roche AG and Novartis Pharmaceuticals Corp.

“Valuable contribution”

Managing director and CEO Leslie Chong said: “We look forward to the valuable contribution De Laeufle will make to advance our important immune-oncology programs and are very pleased someone with her track record and experience is joining Imungene as chief medical officer.”

Laeufle holds Medical Doctor and Doctor of Philosophy degrees from the Albert Ludwig University Freiburg i.Br. Germany – her PhD subject was expression of neu/c-erB-2 (HER-2) in human brain tumors.

Most recently, Laeufle was the chief medical officer at leading oncolytic virus company Oncolytic Biotech in San Diego, California, where she will be based.

Safer treatments for the benefit of patients

Imugene executive chairman Paul Hopper said: “Rita adds a critical capability to our senior leadership team and we are pleased to welcome her to Imugne.

“We thank Dr Marino for his valuable contribution over the past two years and we wish him well in his future endeavours.”

Laeufle said: “Today, our knowledge and understanding of cancer biology has reached new dimensions.

“I am enthusiastic to join this wonderful team of experts at Imugene, together we will drive towards better and safer treatments for the benefit of patients.”

Quick facts: Imugene Ltd

Price: 0.06 AUD

ASX:IMU
Market: ASX
Market Cap: $263.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong says Roth Capital Partners' report is 'great...

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott following the news California-based investment bank Roth Capital Partners has initiated coverage with a Buy rating and a 12-month price target of 13 cents. She says it's a great accomplishment for...

2 weeks, 6 days ago

2 min read